




Frá landnámi til FarGen 2


Noomi Oddmarsdóttir Gregersen, PhD, Ílegusavnið

23. september 2022

Frá landnámi til FarGen 2




Als et al. 2006, Hagstova Føroya



FarGen – eitt undirstøðukervi til gransking


Luttakarar




Laboratorium





Whole-genome sequencing





Whole-exome sequencing



Targeted-panel sequencing





Bioinformatikk



Ein typiskur FarGen-luttakari


- Kvinna, 52 ára gomul, lærari og búsitandi í Havn
- Hon rørir seg eini 3-6 tímar um vikuna og hevur góða heilsustøðu
- Henni feilar onki, men hon sigur, at fleiri í hennara familju hava stoffskiftissjúku
- Hon hevur teknað seg til FarGen, tí tað hevur týðning fyri hana:
 1. at granskingarførleikar verða mentir í Føroyum
 2. at FarGen er ein føroysk verkætlan
 3. at hennara luttøka í gransking kann hjálpa øðrum
- Hon vil eisini fegin luttaka í allari gransking innan heilsuøkið





Heilsustøða hjá FarGen-luttakarum

- Sjálvfráboðað heilsustøða
- Frísk/sjúk lutfall er 1:1
- Nógvar móguligar verkætlanir

Diagnosir í FarGen






Exom-dátur

FarGen 2

- Málið við FarGen 2-verkætlanini er at savna tilfar og fáa kanningar í lag, sum kunnu menna persónlagað medisin í Føroyum
- Málið er at fáa 3500 luttakarar




Hvat gera vit í FarGen 2?


Kanna fyra ymsar sjúkur:

- Ílegur
- Biokemi
 - Blóðprosent, kolesterol, sukur í blóðinum, nýravirkni, livravirkni, stoffskifti, bruna, vitaminir
- Kropslig mát
 - vekt, hædd, feittprosent, vøddamassa, blóðtrýst, puls, lungna- og eygnavirkni

Endamál 2: GWAS




Endamál 1: Tilvísingargenom



- Heilgenom-sekvensering
- Menna eitt føroyskt tilvísingargenom
- Framhald frá FarGen 1

Endamál 3: Pop. genetik



- Kanna, hvussu tætt skyldir føroyingar eru í dag
- Fáa meira kunnleika um upprunan hjá føroysku poplutióinini

Hvussu gera vit FarGen II?



Rekruttering




Laboratorium




Whole-genome sequencing



Kanningar



Persónlagað medisín






FarGen bygnaður


FarGen undirstøðukervið




Whole-genome sequencing



Gransking



Persónlagað medisín



FarGen samstarv

The Genetic Biobank of the Faroe Islands, FarGen

Guðrið Andorsdóttir, MSc, CEO

Noomi O. Gregersen, PhD, project manager

Katrin D. Apól, MA, communication manager

Leivur N. Lydersen, Cand.polyt., laboratory manager and AWS administrator

National Hospital of the Faroe Islands

Bjarni á Steig, MD, clinical leader

Kári Rubek Nielsen, MD, chief physician in diseases of the digestive system

Herborg L. Johannesen, MD, chief physician in diabetes and endocrinology

Jóhan Petur Weihe, MD, chief physician in rheumatism

Torkil á Steig, MD, chief physician in diseases of the circulatory system

Variant Bio, USA

Kaja Wasik, PhD, CSO, Co-Founder

Stephane E. Castel, PhD, Co-founder, CTO

Andrew Farnum, CEO

Globe Institute, University of Copenhagen, Denmark

Assistant Professor Fernando Racimo

Center of Genomic Medicine, Rigshospitalet, Denmark

Professor Finn Cilius Nielsen



kanning.fargen.fo



....og tala til fyriskipta hanna



Vísinda) *vøka*